Joseph Lane, MD
Orthopaedic Surgery · New York, NYNPI 1144245747
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,750 of the $24,860 with a category attached, or 83.5%. 11 manufacturers reported payments, led by Lenoss Medical Inc at 57.3% of the total. Reporting peaked in 2021 at $9,672 and has fallen 95.3% since, to $458 in 2025.
Across 129 payments — averaging $192.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lenoss Medical Inc$14K
- Amgen$4K
- UCB SA$4K
- Radius Health, Inc.$1K
- Stryker$827
- Arteriocyte Medical Systems, Inc.$144
- plus $465 from 5 others
Across 9 payments — averaging $12,753 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Radius Health, Inc.$110K
- Amgen$3K
- Novartis$2K
What the payments were for
- Consulting fees$20,75083%
- Food & beverage$3,92316%
- Education$1871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lenoss Medical Inc | 3 | $14,250 |
| Amgen | 41 | $3,949 |
| UCB SA | 1 | $3,880 |
| Radius Health, Inc. | 37 | $1,346 |
| Stryker | 41 | $827 |
| Arteriocyte Medical Systems, Inc. | 1 | $144 |
| AstraZeneca | 1 | $134 |
| Terumo BCT, Inc. | 1 | $128 |
| Kuros Biosciences USA, Inc | 1 | $101 |
| Cerapedics Inc. | 1 | $99 |
| Si-bone, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Access & Cavity Creation Kit$14,250
- EVENITY$2,620
- Tymlos$225
- Magellan$144
- Strensiq$134
- Bone Marrow Aspirate Concentrate System$128
- MagnetOs$101
How this compares
$24,860 in reported general payments places this provider in the 75th percentile of 1,079 orthopaedic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 513 | $1,398,624 |
| Teriparatide | 141 | $380,723 |
| ForteoTeriparatide | 79 | $334,225 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 22 | $57,175 |
| ProliaDenosumab | 18 | $29,482 |
| Calcitriol | 94 | $2,516 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 27 | $1,429 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 27 | $1,336 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 14 | $790 |
| Alendronate Sodium | 111 | $777 |
| Diclofenac Sodium | 23 | $704 |
| Meloxicam | 33 | $199 |
| Hydrochlorothiazide | 13 | $181 |
| Unifine PentipsPen Needle, Diabetic | 11 | $0 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $1,346 | $1,398,624513 claims |
| AmgenEvenity (2 Syringes), Prolia | $3,949 | $86,65640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,079 orthopaedic surgery providers in New York.
Other orthopaedic surgery in New York
- Anthony RomeoNew York$26.8M
- Lawrence LenkeNew York$26.8M
- Edwin SuNew York$13.2M
- William RicciNew York$11.6M
- Steven HaasNew York$11.3M
- Giles ScuderiNew York$10.7M
- Joseph ZuckermanNew York$9.9M
- Evan FlatowNew York$9.6M
- Bradford ParsonsNew York$9.4M
- Geoffrey WestrichNew York$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.